Feb 18 () - Eli Lilly said on Wednesday its weight-loss drug, Zepbound, used with psoriasis treatment Taltz, showed ‌better ...

Eli Lilly and Co. LLY on Wednesday shared topline results from the landmark TOGETHER-PsO open-label Phase 3b trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) ...

Eli Lilly trades near historical P/E means of ~30x with a 3Y PEG of 1.13x, offering attractive long-term upside potential. Click here to read why LLY is a Buy.

Pharmaceutical giant Eli Lilly and Company (NYSE:LLY)’s shares are up by 23.5% over the past year and down by more than 1% year-to-date.

At 36 weeks in the TOGETHER-PsO study, concomitant Taltz and Zepbound met primary endpoint of superiority vs. Taltz monotherapy in achieving complete skin clearance ...

Novo Nordisk stock sinks 21% in a month as weak 2026 guidance, slowing semaglutide sales, and rising competition overshadow ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Novo Nordisk plans to sell Wegovy in vials in the U.S., expanding options as it competes with Eli Lilly in the growing weight ...

How Low Is Too Low? (Downgrade, Technical Analysis) Novo Nordisk: Ugly Guidance, But Stock Refuses To Break Down Further Novo ...

It's unclear what Novo will charge for vials, but the company already has been aggressively discounting its obesity drugs to ...

The prevailing idea has been that a pill is easier to take, it's cheaper and it doesn't require refrigeration like Wegovy and ...

Shanghai Shiling Pharmaceutical is aiming to complete global clinical trials by 2028 for an experimental weight-management ...